NEW ORLEANS, LA–(Marketwired – May 19, 2017) – Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit against Akari Therapeutics, Plc (
What You May Do
If you purchased securities of Akari Therapeutics and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by July 11, 2017.
About the Lawsuit
Akari Therapeutics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company’s CEO, and possibly others, caused false information about the Company to be published, including but not limited to, false information regarding the Phase 2 PNH trial of Coversin; (ii) the Company lacked adequate measures to prevent such behavior; and (iii) as a result of the foregoing, Akari Therapeutics’ financial statements were materially false and misleading at all relevant times.
On this news, the price of Akari Therapeutics’ shares plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
206 Covington St.
Madisonville, LA 70447